Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an inteferon-gamma receptor/IgG1 fusion protein

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 771-777

  Prud'Homme, G J ^a   Chang, Y ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Autoimmunity; Diabetes; Interferon gamma; Interferon gamma receptor; Intramuscular; Naked DNA

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DNA; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G1; NITRIC OXIDE; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; EXPRESSION VECTOR; FEMALE; GENE THERAPY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; ISLETS OF LANGERHANS; MACROPHAGE ACTIVATION; MICE; MICE, INBRED NOD; PLASMIDS; RECEPTORS, INTERFERON; RECOMBINANT FUSION PROTEINS;

ANIMALIA; MURINAE;

EID: 0033020168     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300879     Document Type: Article

References (38)

1. De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson A (ed). The Cytokine Handbook. Academic Press: San Diego, 1998, pp 491-516.
2. Billiau A. Interferon-gamma in autoimmunity. Cytokine Growth Factor Rev 1996; 7: 25-34.
3. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infections, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532-562.
4. Yoon JW, Jun HS, Santamania P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 1998; 27: 109-122.
5. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 727-738.
6. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87: 739-742.
7. Nicoletti F et al. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinol 1996; 137: 5567-5575.
8. Rothe H et al. Cyclophosphamide treatment of female NOD mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not IL-4. Diabetologia 1994; 37: 1154-1158.
9. Piccirillo C, Chang Y, Prud'homme GJ. Transforming growth factor beta-1 (TGF-beta-1) somatic gene therapy prevents autoimmune disease in NOD mice. J Immunol 1998; 161: 3950-3956.
10. Charlton B, Bacelj A, Slattery RM, Mandel TE. Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 1989; 38: 441-447.
11. Wolff JA et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
12. Raz E et al. Modulation of disease activity in murine lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
13. Giladi E et al. Transforming growth factor-beta gene therapy ameliorates experimental colitis in rats. Eur J Gastroenterol Hepatol 1995; 7: 341-347.
14. Haworth C, Maini RN, Feldmann M. Cytokine and anti-cytokine therapy. In: Thomson A (ed). The Cytokine Handbook. Academic Press: San Diego, 1998, pp 777-801.
15. Hartikka J et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7: 1205-1217.
16. - production as a sensitive and rapid assay for quantitation of murine IFN-gamma. J Immunol Meth 1991; 139: 107-114.
17. Havell EA. Purification and further characterization of an anti-murine interferon-gamma monoclonal neutralizing antibody. J Interferon Res 1986; 6: 489-497.
18. Cockfield SM, Ramassar V, Urmson J, Halloran PF. Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma. J Immunol 1989; 142: 1120-1128.
19. Prud'homme GJ. Cytokines and autoimmunity. In: Bona CA, Siminovitch KA, Zanetti M, Theofilopoulos AN (eds). The Molecular Pathology of Autoimmune Diseases. Harwood Academic Publishers: Chur, Switzerland, 1993, pp 149-168.
20. Prud'homme GJ. Quantitative polymerase chain reaction analysis reveals marked overexpression of IL-1-beta, IL-10, and interferon-gamma in the lymph nodes of lupus-prone mice. Mol Immunol 1995; 32: 495-503.
21. Sarvetnick N et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990; 346: 844-847.
22. Wang B et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 13844-13849.
23. Kürschner C, Ozmen L, Garotta G, Dembic Z. IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenecity, and in vivo activity. J Immunol 1992; 144: 4096-4100.
24. Baquerizo H, Rabinovitch A. Interferon-gamma sensitizes rat pancreatic islet cells to lysis by cytokines and cytotoxic cells. J Autoimmunity 1990; 3 (Suppl. 1): 123-130.
25. Pukel C, Baquerizo H, Rabinovitch A. Destructive of rat islet cell monolayers by cytokines. Synergestic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and IL-1. Diabetes 1988; 37: 133-136.
26. Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by IL-1. J Biol Chem 1997; 272: 13697-13704.
27. McDaniel ML et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 1996; 211: 24-32.
28. Cetkovic-Cvrlje M, Eizirik DL. TNF-alpha and IFN-gamma potentiate the deleterious effects of IL-1 beta on mouse pancreatic islets via generation of nitric oxide. Cytokine 1994; 6: 399-406.
29. Heller B et al. Analysis of oxygen radical toxicity in pancreatic islets at the single cell level. Biol Chem Hoppe-Seyler 1994; 375: 597-602.
30. Lee KU, Amano K, Yoon JW. Evidence for initial involvement of macrophages in development of insulitis in NOD mice. Diabetes 1988; 37: 989-991.
31. Haak-Frendscho M et al. Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin. Immunol 1993; 79: 594-599.
32. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483-1489.
33. Kürschner C, Garotta G, Dembic Z. Construction, purification, and characterization of new interferon gamma inhibitor proteins. J Biol Chem 1992; 267: 9354-9360.
34. Capon DJ et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337: 525-531.
35. Wells KE et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle. FEBS Letts 1997; 407: 164-168.
36. Coligan JE et al. Current Protocols in Immunology. John Wiley and Sons: New York, 1991, pp 8.10.1-8.10.17.
37. Liang L, Beshay E, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 1998; 47: 570-575.
38. Herold KC et al. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1997; 158: 984-991.